A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.

This study employs a multicenter randomized controlled trial design, led by the First Affiliated Hospital of Air Force Medical University (Xijing Hospital) in collaboration with 10 other domestic medical institutions, for a total of 11 research centers. The study plans to enroll a total of 120 HER-2-positive gastric cancer patients, including those who drop out, and randomize them into two groups in a 1:1 ratio; The control group received treatment based on gastric cancer stage: Stage IB patients were treated with tegafur monotherapy (40-60 mg orally twice daily based on body surface area, on

Trial Details

NCT ID
NCT07788196
Phase
PHASE2
Sponsor
Xijing Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Trastuzumab
  • Monotherapy with tegafur for stage IB gastric cancer
  • Stage II gastric cancer treated with the SOX or XELOX regimens
Locations (sample)
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Age ≥ 18 years; Open to all genders;
  • Patients with a definitive histopathological diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, and an ECOG score ≤ 2;
  • Gastric cancer or gastroesophageal junction cancer with TNM stage IB-II;
  • HER-2-positive (IHC 3+ or IHC 2+ with amplification confirmed by FISH/SISH/CISH);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →